Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer Research (AACR) Annual Meeting...
April 19 2016 - 9:00AM
Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical
company, today announced the presentation of data highlighting the
preclinical development of orally bioavailable, potent and
selective checkpoint kinase 1 (Chk1) inhibitors. Results were
presented at the American Association for Cancer Research (AACR)
Annual Meeting 2016 in New Orleans.
Chk1 is a protein kinase that plays a major role
in the ability of cancer cells to respond to DNA damage and DNA
replication stress. As a single agent, Chk1 inhibitors may
selectively target cancer cells that have high replication stress,
which can be caused by activation of oncogenic signaling and loss
of tumor suppressor functions. Chk1 inhibitors may also be used in
combination with chemotherapy, potentially enhancing cell death and
increasing the efficacy of these agents.
“The research presented at AACR describes the
results of our efforts to identify highly potent and selective,
orally bioavailable Chk1 inhibitors with compelling single-agent
and combinatorial anti-tumor activity,” said Scott Peterson, Ph.D,
Chief Scientific Officer of Oncothyreon. “We believe the Chk1
program warrants further study as part of our strategy to develop a
pipeline of novel, orally available, targeted agents designed to
improve the lives and outcomes of patients with cancer.”
The Oncothyreon presentation, titled “Discovery
and development of orally available subnanomolar potent checkpoint
kinase 1 inhibitors as potential anticancer therapies”
(Abstract #2721), highlights preclinical data demonstrating
that select Chk1 inhibitors display subnanomolar biochemical and
single-digit nanomolar cellular potency against Chk1. In
addition, Oncothyreon Chk1 inhibitors are active against a diverse
range of cancer cell lines derived from leukemias, lymphomas and
solid tumors, and demonstrate synergistic activity in combination
with the chemotherapeutic drugs gemcitabine or cytarabine. The
pharmaceutical properties of the Chk1 inhibitors also indicate good
metabolic stability and pharmacokinetic properties, with good oral
bioavailability in preclinical models, which may allow for the
development of optimized dosing schedules.
The research was conducted pursuant to a
research collaboration agreement with Sentinel Oncology.
About Oncothyreon
Oncothyreon is a clinical-stage
biopharmaceutical company specializing in the development of
innovative therapeutic products for the treatment of cancer. Our
goal is to discover, develop and commercialize novel compounds that
have the potential to improve the lives and outcomes of cancer
patients. Our most advanced product candidate is ONT-380, an orally
active and selective small molecule HER2 inhibitor. For more
information, visit www.oncothyreon.com.
Forward-Looking Statements
In order to provide Oncothyreon’s investors with
an understanding of its current results and future prospects, this
release contains statements that are forward-looking. Any
statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements.
Words such as “believes,” “anticipates,” “plans,” “expects,”
“will,” “intends,” “potential,” “possible” and similar expressions
are intended to identify forward-looking statements. These
forward-looking statements include Oncothyreon’s expectations
regarding clinical and preclinical development activities and
potential benefits of its current and future product
candidates.
Forward-looking statements involve risks and
uncertainties related to Oncothyreon’s business and the general
economic environment, many of which are beyond its control. These
risks, uncertainties and other factors could cause Oncothyreon’s
actual results to differ materially from those projected in
forward-looking statements, including the risks associated with the
costs and expenses of developing its product candidates, the
adequacy of financing and cash, cash equivalents and investments,
changes in general accounting policies, general economic factors,
achievement of the results it anticipates from its preclinical
development and clinical trials of its product candidates and its
ability to adequately obtain and protect its intellectual property
rights. Although Oncothyreon believes that the forward-looking
statements contained herein are reasonable, it can give no
assurance that its expectations are correct. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement. For a detailed description of Oncothyreon’s
risks and uncertainties, you are encouraged to review the documents
filed with the securities regulators in the United States on EDGAR
and in Canada on SEDAR. Except as required by law, Oncothyreon does
not undertake any obligation to publicly update its forward-looking
statements based on events or circumstances after the date
hereof.
Additional Information
Additional information relating to Oncothyreon
can be found on EDGAR at www.sec.gov and on SEDAR at
www.sedar.com.
Investor Contact:
Julie Rathbun
Rathbun Communications
206-769-9219
ir@oncothyreon.com
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Apr 2023 to Apr 2024